{"nctId":"NCT03078075","briefTitle":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","startDateStruct":{"date":"2017-05-05","type":"ACTUAL"},"conditions":["Methamphetamine Use Disorder"],"count":403,"armGroups":[{"label":"Active Medication Combination (AMC)","type":"EXPERIMENTAL","interventionNames":["Drug: Naltrexone: Vivitrol®","Drug: Bupropion: Wellbutrin XL®"]},{"label":"Matched Placebo (PLB)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (PLB) Injectable","Drug: Placebo (PLB) Oral"]}],"interventions":[{"name":"Naltrexone: Vivitrol®","otherNames":["Arm: Experimental - Active Medication Combination (AMC)"]},{"name":"Placebo (PLB) Injectable","otherNames":["Injectable matching (to Naltrexone) placebo","Arm: Placebo Comparator - matched Placebo (PLB)"]},{"name":"Bupropion: Wellbutrin XL®","otherNames":["Arm: Experimental - Active Medication Combination (AMC)"]},{"name":"Placebo (PLB) Oral","otherNames":["Oral matching (to Bupropion) placebo tablets","Arm: Placebo Comparator - matched Placebo (PLB)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 65 years old;\n* Interested in reducing/stopping methamphetamine use;\n* Speak English;\n* Agree to use acceptable birth control (if applicable);\n* Be opioid-free at randomization;\n* Willing to comply with all study procedures and medication instructions;\n* Agree to use a cell phone (or similar study device) to take videos of medication dosing.\n\nExclusion Criteria:\n\n* Medical or psychiatric condition which would make participation unsafe;\n* Recently participated in a study of pharmacological or behavioral treatment for methamphetamine use disorder;\n* Recently taken an investigational drug;\n* Prescribed and taken naltrexone or bupropion ≤ 30 days from consent;\n* Current or planned extended absence during study period (e.g., jail, surgery, pending legal action);\n* Currently pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Response During Medication Phase at Stage 1","description":"Treatment response is defined as 'Responder' and 'Non-Responder'.\n\nResponder : Participant who meet responder criterion by providing at least 3 out of a possible 4 methamphetamine-negative urine tests at the end of stage 1 (weeks 5-6).\n\nNon-Responder: All other participants without 3 or 4 methamphetamine-negative UDS (Urine Drug Screen).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null}]},{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Response During Medication Phase at Stage 2","description":"Treatment response is defined as 'Responder' and 'Non-Responder'.\n\nResponder : Participant who meet responder criterion by providing at least 3 out of a possible 4 methamphetamine-negative urine tests at the end of stage 1 (weeks 5-6).\n\nNon-Responder: All other participants without 3 or 4 methamphetamine-negative UDS.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Effectiveness Score of Participants at Stage 1","description":"The Treatment Effectiveness Score (TES) as measured by UDS results, during the treatment period. The TES is the percentage of the expected urine drug screens that were negative for each drug. Twelve urine drug screens are expected within each stage.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.72","spread":"13.41"},{"groupId":"OG001","value":"13.84","spread":"22.97"}]}]}]},{"type":"SECONDARY","title":"Treatment Effectiveness Score of Participants at Stage 2","description":"The Treatment Effectiveness Score (TES) as measured by UDS results, during the treatment period. The TES is the percentage of the expected urine drug screens that were negative for each drug. Twelve urine drug screens are expected within each stage. The range of possible scores are 0-100 and higher score indicates better outcomes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.45","spread":"16.02"},{"groupId":"OG001","value":"11.55","spread":"24.55"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Used Methamphetamine in the Pre-evaluation Period","description":"Methamphetamine use, as measured by UDS (urine drug screen) in the pre-evaluation period (Weeks 1-4 for Stage 1 and Weeks 7-10 for Stage 2 )","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.10","spread":null},{"groupId":"OG001","value":"11.93","spread":null},{"groupId":"OG002","value":"7.95","spread":null},{"groupId":"OG003","value":"10.20","spread":null},{"groupId":"OG004","value":"29.46","spread":null},{"groupId":"OG005","value":"22.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Maximum Number of Consecutive Visits Negative UDS at Stage 1","description":"Measured by maximum consecutive negative UDS: Count the number and range 0-12 and report the maximum number.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"1.31"},{"groupId":"OG001","value":"1.37","spread":"2.50"}]}]}]},{"type":"SECONDARY","title":"Mean Maximum Number of Consecutive Visits Negative UDS at Stage 2","description":"Measured by maximum consecutive negative UDS: Count the number and range 0-12 and report the maximum number.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"1.46"},{"groupId":"OG001","value":"1.18","spread":"2.72"},{"groupId":"OG002","value":"3.10","spread":"4.39"},{"groupId":"OG003","value":"2.63","spread":"4.13"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Study Weeks With Two Methamphetamine-negative UDS at Stage 1","description":"Measured by the number of study weeks during the treatment period with two methamphetamine-negative UDS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.55"},{"groupId":"OG001","value":"0.56","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Study Weeks With Two Methamphetamine-negative UDS at Stage 2","description":"Measured by the number of study weeks during the treatment period with two methamphetamine-negative UDS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.70"},{"groupId":"OG001","value":"0.50","spread":"1.35"},{"groupId":"OG002","value":"1.48","spread":"2.21"},{"groupId":"OG003","value":"1.20","spread":"2.08"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Percentage of Methamphetamine Abstinent Days Measured by Self-report at Stage 1","description":"Methamphetamine use selfreported on TLFB ( Timeline Followback) during the follow-up period.\n\nThe baseline measure is the percentage of abstinent days in the 30 days prior to randomization. The outcome is the change in percentage of abstinent days.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"1.3"},{"groupId":"OG001","value":"27.2","spread":"2.88"}]}]}]},{"type":"SECONDARY","title":"Mean Change Percentage of Methamphetamine Abstinent Days Measured by Self-report at Stage 2","description":"Methamphetamine use selfreported on TLFB ( Timeline Followback) during the follow-up period.\n\nThe baseline measure is the percentage of abstinent days in the 30 days prior to randomization. The outcome is the change in percentage of abstinent days.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":"1.5"},{"groupId":"OG001","value":"25.3","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Methamphetamine Craving at Stage 1","description":"Severity of methamphetamine craving, as measured by Visual Analog Craving Scales (VAS), during the treatment period. VAS scores range from 0 (no craving) to 100 (most intense craving possible). The VAS is completed at screening, once a week during the treatment period, and at the follow-up visits.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.33","spread":"1.82"},{"groupId":"OG001","value":"-29.98","spread":"3.17"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Methamphetamine Craving at Stage 2","description":"Severity of methamphetamine craving, as measured by Visual Analog Craving Scales (VAS), during the treatment period. VAS scores range from 0 (no craving) to 100 (most intense craving possible). The VAS is completed at screening, once a week during the treatment period, and at the follow-up visits.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.52","spread":"1.72"},{"groupId":"OG001","value":"-31.79","spread":"3.17"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Abstinent Days of Participants Who Used Other Substance Measured by UDS at Stage 1","description":"Other substance use including Amphetamine, Non-Methamphetamine Drug, Cocaine, Alcohol, Cigarettes, as measured by UDS, during the treatment period. Opioid use will also be assessed using the Opioid 2000 ng tests on the UDS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.89","spread":"1.0"},{"groupId":"OG001","value":"41.95","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.53","spread":"14.7"},{"groupId":"OG001","value":"31.47","spread":"13.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.87","spread":"0.6"},{"groupId":"OG001","value":"41.87","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.44","spread":"9.5"},{"groupId":"OG001","value":"37.89","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.29","spread":"18.7"},{"groupId":"OG001","value":"16.31","spread":"18.2"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Abstinent Days of Participants Who Used Other Substance Measured by UDS at Stage 2","description":"Other substance use including Amphetamine, Non-Methamphetamine Drug, Cocaine, Alcohol, Cigarettes, as measured by UDS, during the treatment period. Opioid use will also be assessed using the Opioid 2000 ng tests on the UDS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.96","spread":"0.3"},{"groupId":"OG001","value":"44.95","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.99","spread":"15.2"},{"groupId":"OG001","value":"31.05","spread":"16.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":"0.4"},{"groupId":"OG001","value":"44.88","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.41","spread":"11.9"},{"groupId":"OG001","value":"39.91","spread":"9.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.11","spread":"20.0"},{"groupId":"OG001","value":"19.31","spread":"20.1"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Proportion of Other Substance Abstinent Days Measured by Self-report at Stage 1","description":"Proportion of abstinent days of other substance including Alcohol, Cigarettes and E- Cigarettes was measured by self-report on TLFB during the treatment period.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.054","spread":"0.011"},{"groupId":"OG001","value":"-0.016","spread":"0.017"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.054","spread":"0.010"},{"groupId":"OG001","value":"0.103","spread":"0.021"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.064","spread":"0.009"},{"groupId":"OG001","value":"-0.072","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Proportion of Other Substance Abstinent Days Measured by Self-report at Stage 2","description":"Proportion of abstinent days of other substance including Alcohol, Cigarettes and E- Cigarettes was measured by self-report on TLFB during the treatment period.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.035","spread":"0.012"},{"groupId":"OG001","value":"-0.035","spread":"0.016"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":"0.012"},{"groupId":"OG001","value":"0.119","spread":"0.022"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":"0.011"},{"groupId":"OG001","value":"-0.079","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Number of Other Substance Use by Self-report at Stage 1","description":"Number of other substance (Alcohol and Cigarettes) use was measured by self-report recall on Timeline Followback (TLFB) during the treatment period.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.358","spread":"1.503"},{"groupId":"OG001","value":"-1.604","spread":"3.290"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.642","spread":"7.221"},{"groupId":"OG001","value":"-55.873","spread":"14.154"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Number of Other Substance Use by Self-report at Stage 2","description":"Number of other substance (Alcohol and Cigarettes) use was measured by self-report recall on Timeline Followback (TLFB) during the treatment period.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.695","spread":"1.779"},{"groupId":"OG001","value":"-2.942","spread":"3.121"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.925","spread":"7.801"},{"groupId":"OG001","value":"-58.591","spread":"14.594"}]}]}]},{"type":"SECONDARY","title":"Change in Proportion of E-cigarettes Abstinent Days by Self-report at Stage 1","description":"Proportion of abstinent days of E- Cigarettes was measured by self-report at stage 1.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.064","spread":"0.009"},{"groupId":"OG001","value":"-0.072","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Change in Proportion of E-cigarettes Abstinent Days by Self-report at Stage 2","description":"Proportion of abstinent days of E- Cigarettes was measured by self-report at stage 2.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":"0.011"},{"groupId":"OG001","value":"-0.079","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Depression Symptom Score by PHQ-9 at Stage 1","description":"Patient Health Questionnaire-9 (PHQ-9) measures participants depression symptoms. Possible scores range from 0-27, with higher scores indicating a more severe depression symptoms.\n\nPHQ-9 scores reflect depression severity, ranges from 0-27 (0 no depressive symptoms, 1-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.26","spread":"0.34"},{"groupId":"OG001","value":"-4.78","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Depression Symptom Score by PHQ-9 at Stage 2","description":"Patient Health Questionnaire-9 measures participants depression symptoms. Possible scores range from 0-27, with higher scores indicating a more severe depression symptoms.\n\nPHQ-9 scores reflect depression severity, ranges from 0-27 (0 no depressive symptoms, 1-4 minimal depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, 20-27 severe depression)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.66","spread":"0.37"},{"groupId":"OG001","value":"-4.39","spread":"0.64"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Quality of Life (QOL) by PhenX Core Tier 1 Instrument at Stage 1","description":"Mean change score of QOL (General health, Physical health, and Mental health) from baseline will be assessed by PhenX (Phenotypes and eXposures) Core Tier 1 instrument: Quality of Life (QOL), which measures participants' quality of life during the past 30 days. Possible scores range from 0 to 30 (number of days in the past 30 in which health was good), with higher scores indicating a better quality of life.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.013","spread":"0.805"},{"groupId":"OG001","value":"1.425","spread":"1.225"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.071","spread":"0.842"},{"groupId":"OG001","value":"3.785","spread":"1.380"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.168","spread":"0.957"},{"groupId":"OG001","value":"1.582","spread":"1.442"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Quality of Life (QOL) by PhenX Core Tier 1 Instrument at Stage 2","description":"Mean change score of QOL (General health, Physical health, and Mental health) from baseline will be assessed by PhenX Core Tier 1 instrument: Quality of Life (QOL), which measures participants' quality of life during the past 30 days. Possible scores range from 0 to 30 (number of days in the past 30 in which health was good), with higher scores indicating a better quality of life.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.877","spread":"0.870"},{"groupId":"OG001","value":"1.561","spread":"1.147"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.035","spread":"0.917"},{"groupId":"OG001","value":"2.821","spread":"1.345"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.262","spread":"1.038"},{"groupId":"OG001","value":"0.152","spread":"1.365"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Overall Functioning as Measured by Treatment Effectiveness Assessment (TEA) at Stage 1","description":"The Treatment Effectiveness Assessment is a 4-item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, health, lifestyle, and community and is collected at screening, mid-treatment (Week 6 Visit 2) and end-of-treatment (Week 12 Visit 2).\n\nPossible scores range from 4-40, with higher scores indicating a higher overall functioning.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.0"},{"groupId":"OG001","value":"6.5","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Mean Change of Overall Functioning as Measured by Treatment Effectiveness Assessment (TEA) at Stage 2","description":"The Treatment Effectiveness Assessment is a 4-item self-administered assessment that uses a Likert scale (1-10) to document changes in four life domains: substance use, health, lifestyle, and community and is collected at screening, mid-treatment (Week 6 Visit 2) and end-of-treatment (Week 12 Visit 2).\n\nPossible scores range from 4-40, with higher scores indicating a higher overall functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.1"},{"groupId":"OG001","value":"6.2","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Completed the Visit in Week 12","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Satisfaction Rating Measured by Study Satisfaction Survey at the End of the Study","description":"The Study satisfaction survey measures participants satisfaction. We do not have a proper score range (varied range with some free text questions also)","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":294},"commonTop":["Nausea"]}}}